Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 30, 2026 10:59 ET | Source: Elevar Therapeutics

Elevar Therapeutics Announces FDA Acceptance of New Drug Application Resubmission for Rivoceranib in Combination with Camrelizumab as a First-line Systemic Treatment for Unresectable Hepatocellular Carcinoma

FORT LEE, N.J., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating...
January 29, 2026 12:01 ET | Source: AB Science

AB Science reçoit un avis d'autorisation pour un brevet américain couvrant le masitinib dans le traitement du cancer de la prostate métastatique hormono-resistant

COMMUNIQUÉ DE PRESSE AB SCIENCE REÇOIT UN AVIS D'AUTORISATION POUR UN BREVET AMÉRICAIN COUVRANT LE MASITINIB DANS LE TRAITEMENT DU CANCER DE LA PROSTATE MÉTASTATIQUE HORMONO-RESISTANT CETTE DÉCISION...
January 29, 2026 12:01 ET | Source: AB Science

AB Science receives notice of allowance for US patent covering masitinib in the treatment of metastatic castrate resistant prostate cancer

PRESS RELEASE AB SCIENCE RECEIVES NOTICE OF ALLOWANCE FOR UNITED STATES PATENT COVERING MASITINIB IN THE TREATMENT OF METASTATIC CASTRATE RESISTANT PROSTATE CANCER THIS POSITIVE DECISION FROM THE...
January 29, 2026 10:46 ET | Source: Quetzal Therapeutics

QTX-2101 Awarded FDA Fast Track Designation for the Treatment of Acute Promyelocytic Leukemia

CHICAGO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Quetzal Therapeutics, a biopharmaceutical company focused on developing treatments for rare diseases, announced that the U.S. Food and Drug Administration...
January 29, 2026 09:00 ET | Source: Panakeia Technologies Ltd

Panakeia publishes landmark clinical validation showing AI can deliver rapid molecular profiling for colorectal cancer

Panakeia publishes landmark clinical validation showing AI can deliver rapid molecular profiling for colorectal cancer
January 29, 2026 08:00 ET | Source: Revolution Medicines, Inc.

Revolution Medicines Doses First Patient in Clinical Trial Evaluating RMC-5127, a RAS(ON) G12V-Selective Inhibitor

REDWOOD CITY, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today...
January 29, 2026 02:30 ET | Source: Enterome

Enterome appoints leading hematologist and IFLI Executive Partner Mehrdad Mobasher, M.D., M.P.H., to its Board of Directors

Dr. Mobasher held several executive roles in industry, most recently CMO at BeiGeneIFLI contributed up to $9 million to Enterome’s private funding round in 2025Enterome has announced a series of...
January 28, 2026 12:00 ET | Source: Siren Biotechnology, Inc.

Siren Biotechnology Announces FDA Clearance of First IND, Advancing Company to Clinical Stage

Siren Biotechnology Announces FDA Clearance of First IND, Advancing Company to Clinical Stage
January 28, 2026 08:00 ET | Source: Calidi Biotherapeutics, Inc

Calidi Biotherapeutics Provides Corporate Update and Key Value Drivers for 2026

Company intends to file an IND in Q4 2026 for its first RedTail lead candidate, CLD-401, a systemically delivered and targeted genetic medicine engineered to deliver high concentrations of IL-15...
January 27, 2026 16:35 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Announces Changes to Key Dates and Terms Related to Announced Rights Offering

OCALA, Fla., Jan. 27, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and...